SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, today reported financial results for the quarter ended March 31, 2014. - See more at: http://www.globenewswire.com/news-release/2014/05/12/635341/10081139/en/Achaogen-Announces-First-Quarter-2014-Results.html#sthash.IM2KSi94.dpuf
Help employers find you! Check out all the jobs and post your resume.
